UVA Health System frequently opens new clinical trials, offering your patients the latest investigational treatments.
For a complete list of active cancer trials and study coordinator contact information, visit our newly launched Find a Clinical Trial website. If you have patients who may be eligible to participate in a cancer clinical trial, please email cancerclinicaltrials@virginia.edu.
Breast Oncology (IRB-HSR #20518)
Single-Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable, Locally-Advanced or Metastatic Triple-Negative Breast Cancer (NCT03310957)
Primary Investigator: Patrick Dillon
Clinical Research Coordinator: Jake Boyd
Breast Oncology (IRB-HSR #20295)
Randomized and Blinded Clinical Evaluation of DermACELL Without Basement Membrane in Breast Reconstruction
Primary Investigator: Patrick Cottler
Clinical Research Coordinator: Dena Synyder
Genitourinary Oncology (IRB-HSR #20610)
ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (NCT03397394)
Primary Investigator: Robert Dreicer
Clinical Research Coordinator: Julio Torres
Hematologic Malignancies (IRB-HSR #20613)
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens
Primary Investigator: Laahn Foster
Clinical Research Coordinators: Michal Ande
Hematologic Malignancies (IRB-HSR #20729)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma
Primary Investigator: Craig Portell
Clinical Research Coordinator: Amelia Hodson, Kristen L. Johnson
Hematologic Malignancies
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML
Primary Investigator: Karen Ballen
Clinical Research Coordinator: Amelia Hodson
Thoracic Oncology (IRB-HSR #20704)
A Randomized Phase II Trial of Docetaxel plus Nivolumab or Docetaxel alone in patients with advanced squamous or non-squamous NSCLC and previous clinical benefit on treatment with a PD-1 or PD-L1 inhibitor (NCT03041181)
Primary Investigator: Richard Hall
Clinical Research Coordinator: Gracie Tubbs Hockenberry
Idiopathic Parkinson’s Disease (IRB-HSR #180001)
A Pivotal Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Idiopathic Parkinson’s Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Neuro System (NCT03319485)
Primary Investigator: W. Jeffrey Elias
Clinical Research Coordinator: Matthew Patterson
Idiopathic Parkinson’s Disease (IRB-HSR #17552)
A Randomized Feasibility Clinical Trial of the Management of the Medically-Refractory Motor Symptoms of Advanced Idiopathic Parkinson’s Disease With Unilateral Lesioning of the Subthalamic Nucleus Using the ExAblate Transcranial System
Primary Investigator: W. Jeffrey Elias
Clinical Research Coordinator: Matthew Patterson
Chronic Trigeminal Neuropathic Pain (IRB-HSR #170004)
A Feasibility Study of Focused Ultrasound to Perform Bilateral Medial Thalamotomy for the Treatment of Chronic Trigeminal Neuropathic Pain (NCT03309813)
Primary Investigator: W. Jeffrey Elias
Clinical Research Coordinator: Matthew Patterson
Newly Diagnosed Glioblastoma (IRB-HSR #19800)
INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT). (NCT02977780)
Primary Investigator: David Schiff
Clinical Research Coordinator: Starlene Truslow
Newly Diagnosed Glioblastoma (IRB-HSR #20105)
A Phase I Study Targeting Newly Diagnosed Glioblastoma with anti-CD3 x anti-EGFR Bispecific Antibody Armed T cells (EGFR BATs) in Combination with Radiation and Temozolomide (NCT03344250)
Primary Investigator: Camilo Fadul
Clinical Research Coordinator: Melissa Otoya
Newly Diagnosed & Recurrent Glioblastoma (IRB-HSR #170002)
A Phase 1b/2 study to assess the safety, tolerability and efficacy of BGB-290 in combination with radiation therapy and/or temozolomide in subjects with first-line or recurrent/refractory glioblastoma (NCT03150862)
Primary Investigator: David Schiff
Clinical Research Coordinator: Carol Woodburn
